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Current laboratory diagnostic assays for Clostridium difficile infection (CDI) vary in their 
performance characteristics, timeliness, and cost. The gold standard diagnostic assay, toxigenic 
culture, has a turnaround time of 4-7 days which makes it impractical for routine clinical use. 
Furthermore, There is no widely accepted standard for the laboratory diagnosis of CDI, and a 
variety of FDA-approved diagnostic assays are used at the discretion of hospital laboratories. 
Therefore, this study was conducted during November 2011-February 2012 on 524 stool samples 
from 427 patients to examine the performance characteristics (sensitivity, specificity, positive 
predictive value, negative predictive value) of five diagnostic assays including newer molecular 
assays. Toxigenic culture was used as the gold standard. To examine the possibility that the 
newer generation of molecular assays are identifying asymptomatic carriers, a retrospective chart 
review was conducted for patients with discrepant test patterns.  
In the absence of clinical data, molecular nucleic acid based assays (RT-PCR, iLAMP) 
possess superior performance characteristics.  Additionally, there are no significant differences 
between mean C. difficile likelihood scores when comparing discrepant groups. Further, when 
examining presence of three main clinical factors including diarrhea, inpatient exposure, and 
antibiotic usage, there was no significant difference in the percentage of patients expressing these 
factors between each discrepant result group. Therefore, it is unlikely to refine the performance 
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characteristics when incorporating clinical data. When examining semi-quantitative toxigenic 
culture which indicated C. difficile concentration in colony forming units per gram, there was no 
significant difference in scores between groups, indicating that C. difficile patients were likely to 
have CDI regardless of concentration. Similarly, the percentage of positive results on each toxin-
detecting assay did not vary significantly.  Furthermore, 54-100% of patients in all semi-
quantitative culture groups possessed all three clinical factors, indicating no relationship between 
presence of these factors and concentration. 
 Public Health Implications: Clostridium difficile infection (CDI) is one of the most 
common healthcare-associated infections. Since its discovery in 1978 as the cause of antibiotic 
associated pseudomembranous colitis, its incidence has increased significantly affecting a greater 
number of populations. Determining a diagnostic assay for use in clinical setting which possesses 
excellent performance characteristics allows for the reduction of disease burden.  
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1.0  INTRODUCTION 
1.1 HEALTHCARE-ASSOCIATED INFECTIONS 
Healthcare-associated infections (HAI) are endemic infections which occur in hospitals and 
long-term care facilities, with the potential for outbreaks. HAIs are typically defined as those 
with symptom onset at least 72 hours after admission and are not present or incubating during 
admission. This definition also includes infections that appear after discharge from the healthcare 
institution. These infections are caused by a variety of causative agents, including bacteria, 
viruses, parasites and fungi. Examples include methicillin resistant Staphylococcus aureus 
(MRSA), Vancomycin-resistant Enterococcus (VRE), urinary tract infection, hospital-acquired 
pneumonia, and Clostridium difficile infections (CDI). A number of factors promote the 
development of nosocomial infections. Inadequate infection control techniques including 
incorrect usage of isolation gowns, gloves, and mask/respirators are an additional risk factor. 
Inadequate environmental sanitation characterized by improper disinfectant usage, inadequate 
frequency and effectiveness of sanitation is a major source of nosocomial infections. 1   
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1.2 CLOSTRIDIUM DIFFICILE 
Clostridium difficile infection (CDI) is an example of a nosocomial infection. This infection is 
caused by the causative organism, Clostridium difficile. First identified in 1935 by Hall and 
O’Toole in gut flora of healthy neonates, C. difficile is an anaerobic gram-positive spore-forming 
bacillus (Figure 1).2  Asymptomatic carriage is of toxin-producing C. difficile is present in 5-
15% of healthy, non-hospitalized and up to 50% of asymptomatic patients with a length of 
hospital stay longer than two weeks.3,4 In 1978, Clostridium difficile was implicated as the cause 
of antibiotic-associated diarrhea and pseudomembranous colitis.5  
 
Figure 1. Scanning electron microscopy of Clostridium difficile bacilli (Centers for 
Disease Control and Prevention) 
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C. difficile infections present with a wide spectrum of severity. Levels of severity range 
from asymptomatic carriage to fulminant pseudomembranous colitis, and toxic megacolon. 
Septic shock and death can occur in the most severe cases.6  The most common presentation 
involves voluminous watery diarrhea and abdominal cramps. C. difficile can be difficult to treat 
due to high occurrence to relapse, with an estimated 25 percent of patients treated for one CDI 
episode experiencing at least one relapse.7,8,9 The chance of relapse increases further as the 
number of CDI episodes increases, with estimates of relapse reaching 50-65 percent.10   
Fecal-oral transmission of this anaerobe is facilitated by the spore forming nature of the 
organism. C. difficile spores are resistant to heat, quaternary ammonium disinfectants, and 
ethanol allowing survival in harsh environmental condition and rendering the organism resistant 
to common hand sanitizers and hospital disinfectants.11  
1.2.1 Pathogenesis 
As with other Clostridium species, toxigenic C. difficile strains produce several toxins which are 
responsible for the infection. The toxin genes are located in the 19.6 kb pathogenicity locus 
(PaLoc) (Figure 2a).12,13 The PaLoc is highly conserved across all toxigenic strains. The PaLoc 
is composed of genes tcdA, tcdB, tcdC, tcdE and tcdR.  Two of the most well characterized 
toxins, Toxin A and Toxin B and are encoded by tcdA and tcdB, respectively.  Toxin A is an 
enterotoxin which has demonstrated the ability to inactivate Rho GTPases. Toxin B is a potent 
cytotoxin, and depolymerizes actin within a wide variety of cell lines through an as-yet-unknown 
receptor.  A holin protein encoded by tcdE may be responsible for the release of toxin from the 
vegetative cell. Supplemental genes, including positive and negative regulators are present on the 
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PaLoc. Gene tcdR is a positive regulator of tcdA and tcdB through its action as a σ-factor, while 
tcdC is a negative regulator of toxin production preventing transcription of the PaLoc.5,12,13  
Another toxin, binary toxin is encoded by the CDT locus 4.3 kb (CdtLoc) (Figure 2b). This 
particular toxin is only found in up to 5-12% of strains. There are two subunits cdtA and cdtB, 
and both are required for pathogenicity. This toxin disrupts the structural integrity of the cell via 
loss of cytoskeleton, and cell contents. Binary toxin is important as it has been found in many 
epidemic strains implicated in outbreaks, however, it has not been found to cause disease in 
animal models of CDI when PaLoc genes are inactivated. There are 28 toxinotypes of C. 
difficile. Most strains of C. difficile possess toxinotypes with functional tcdA and tcdB genes. 
However, an increasing number of strains are being isolated from patients which lack functional 
tcdA toxin due to mutations in the gene.5,14 
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Figure 2. Pathogenicity Locus of Clostridium difficile  
a) The pathogenicity locus (PaLoc) is a 19 kb stretch of DNA composed of five genes, with the 
center holin gene tcdE which is flanked by two toxin genes tcdB and tcdA and is capped by the 
positive and negative regulators, tcdR and tcdC, respectively. b) The binary toxin called C. 
difficile transferase is encoded by the CDT locus containing two subunits cdtA and cdtB  and is 
4.3 kb in length of DNA. In some strains of C. difficile it is a component of pathogenicity. 
Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews Microbiology, 
Rupnik M, et al. 7:532 copyright 2009 (116). 
 
C. difficile is transmitted through the fecal-oral route in spore form and is able to 
withstand the acidic environment of the stomach. Upon advancement through the digestive tract, 
the spores germinate into vegetative cells, reproduce, mature and produce toxins affecting the 
colon leading to development of disease.  
The current hypothesis for successful development of CDI involves three major key 
events.  The first event is antimicrobial exposure which leads to alteration of normal gut flora. 
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This event creates a niche environment for C. difficile to flourish.  The second event involves 
toxigenic C. difficile acquisition before or after the administration of antimicrobials in the 
healthcare setting.  Lastly, there must be a failure of the host to mount an anamnestic IgG 
antibody response to Toxin A.14 This is a key prerequisite event to development of CDI. If the 
preceding two events occur, and the individual mounts an anamnestic IgG response, the 
individual will not develop disease and is likely to in a state of asymptomatic C. difficile 
colonization (Figure 3).5 
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Figure 3. Proposed model for acquisition of Clostridium difficile infection in 
healthcare settings. 
The proposed model of CDI in the healthcare setting is believed to occur when a previously CDI 
negative individual visits a medical facility and acquires C. difficile spores through the fecal-oral 
route, antimicrobials administered either pre- or post-exposure disrupt the gut flora allowing a 
niche environment to form for the organism.  If the organism acquired is non-toxigenic, the 
patient is said to be colonized and patient will not exhibit symptoms.  If the patient acquires a 
toxigenic C. difficile and fails to acquire an anamnestic immunological response IgG to toxin A 
then the patient will present with CDI, otherwise the patient will likely be asymptomatically 
colonized. Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology, Rupnik M, et al. 7:532 copyright 2009 (116). 
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1.2.2 Risk Factors 
A wide variety of risk factors exist for CDI.  The main risk factor for disease is the use of broad-
spectrum antimicrobials including clindamycin, broad spectrum beta-lactams, cephalosporins 
and quinolones. However, almost all antimicrobials have been observed to have an associated 
increased risk of development of disease.15  Recovery of normal gut flora can take up to three 
months after consumption of a course of antibiotics, leading to greater time for vulnerability and 
exploitation by the C. difficile pathogen. The factors that increase risk of CDI include and are not 
limited to advanced age, medical co-morbidities, immunosuppression, recent CDI and healthcare 
exposure.  Other risk factors for development of CDI are listed below (Table I). These include 
highly invasive medical procedures such as surgical procedures involving the abdomen, which 
allow C. difficile spores to enter, colonize, and cause disease.  As previously mentioned, HAIs 
transmission is enhanced through various tubes and drains which breach or bypass the patient 
host defenses and Clostridium difficile is no exception in taking advantage of these breaches. 
One example is nasogastric intubation increase the risk by providing a means for spores to enter 
the abdomen. 16,17,18,19,20,21,22,23  Reduced gastrointestinal pH due to the use of pharmaceutical 
agents, mainly proton pump inhibitors and H2-receptor antagonists, has been shown to be a risk 
factor.24,25  
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Table 1. Risk Factors for development of Clostridium difficile Infection 
 
Advanced age Reduced gastric pH due to use of Proton Pump 
Inhibitors (PPI) and/or H2-receptor antagonists 
Invasive medical procedures Intubation 
Antimicrobial usage Medical Co-morbidities 
Immunosuppression Recent healthcare exposure- Inpatient, 
Outpatient, or Skilled Nursing Facility 
Recent CDI episode 
 
 
1.2.3 Treatment 
A variety of treatment options are available to combat CDI. Accompanying any treatment 
involves the discontinuation of the offending antimicrobials that led to the development of CDI 
episode.  Currently, there are two established efficacious antimicrobial agents which are used to 
treat CDI. These agents are metronidazole (Flagyl) and vancomycin (Vancocin). Metronidazole 
is indicated for mild-moderate cases of CDI. Typical dosage is 500mg three times daily, oral 
administration for 10-14 days. Vancomycin is indicated for severe CDI episodes, with dosages of 
125mg four times daily, oral administration for 10-14 days. In some severe cases, vancomycin is 
administered, rectally via enema form.26 Newer antimicrobial agents such as fidaxomicin, have 
recently been approved by the Food and Drug Administration as of 2011 to treat CDI and is 
being investigated as a possible routine treatment.27 In patients with hypogammaglobulinemia, 
intravenous immunoglobulin (IVIG) is used as another treatment to confer passive immunity. In 
the most severe cases, surgical treatment may be required.24 The surgical procedure typically 
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performed is a colectomy which is the removal of the colon. However, other newer surgical 
procedures have been explored including minimally invasive temporary loop ileostomy with 
vancomycin lavage.28 Other alternative treatments, such as fecal microbiota transplantation 
(FMT), which involves the restoration of beneficial gut flora, are sometimes performed.29 
1.2.4 Prevention 
Because C. difficile can be difficult to treat due to high relapse rates and the overall robust nature 
of the organism, prevention plays an important role in combating disease burden. There are a 
variety of prevention strategies can be used to reduce the burden of disease. Ensuring that each 
category of prevention is properly executed is essential. Surveillance within the healthcare 
institution via infection control personnel precludes any form of prevention. A number of clinical 
practice guidelines for prevention have been identified by experts including the Centers for 
Disease Control (CDC), Society for Healthcare Epidemiology of America (SHEA) and 
Infectious Diseases Society of America (IDSA).    
Effective sanitation in the healthcare setting is an absolute necessity. Because of the spore 
forming nature of the organism, few agents are effective in disinfection. Three established 
disinfectant agents which have been shown to be effective are minimum concentrations of 10% 
sodium hypochlorite (NaOCl), 10% hydrogen peroxide (H2O2) and 2% alkaline glutaraldehyde. 
Other disinfectants such as ethanol and quaternary ammonium compounds, which are highly 
effective against other pathogens, have been shown to be ineffective and in some cases promote 
sporulation. Using effective agents on all surfaces in the healthcare setting, especially patient 
rooms is necessary, no matter how challenging and time consuming this can be. In some cases, 
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the practicality of this is problematic and utilization of disposable healthcare items instead of 
reusable items is preferable. One example is the use of disposable rectal thermometers. The 
practice has been shown to reduce the incidence of CDI.10 
Proper contact precautions can aid in providing a barrier to propagation of the pathogen, 
and have been demonstrated to be effective in prevention.  Ensuring proper compliance among 
healthcare workers with current hand-hygiene protocols emphasizing appropriate time intervals, 
duration of wash, and use of soap and water is one aspect. Proper agitation during hand washing 
facilitates spore removal from contaminated hands.  Expanding this protocol to include visitors 
during outbreaks is advisable. Wearing gloves prevents contamination of the hands with spores 
and should supplement hand hygiene protocol.   Wearing isolation gowns prevents deposition of 
spores on clothing when caring for patients and therefore aids in prevention of CDI. Patient 
placement is important, ensuring that unaffected patients are not placed in close proximity to 
known C. difficile patients. One study suggested that when a patient is placed in a room with a 
prior CDI occupant, the patient faces an 11% risk of developing disease, while those who were 
placed in rooms with patients who were not affected by CDI had only a 4.6% risk.30  
One of the most important prevention strategies is the proper use of antimicrobials. 
Because antimicrobial usage is involved in the pathogenesis of CDI, ensuring antimicrobials are 
only used when necessary is key. It is currently estimated that 50% of all antimicrobial use is of 
inappropriate nature.  Therefore, an excess of patients receiving care are exposed to 
antimicrobials and their gut flora is altered, leading to increased risk of CDI. One way to combat 
this problem within the healthcare institution is the implementation of an antimicrobial 
stewardship program which monitors overall antimicrobial usage and restricts usage of broad-
spectrum, high-risk antimicrobials, to cases which are only necessary.31  
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Other strategies are being researched but have not been adapted by SHEA, IDSA, or 
CDC.  One such strategy is to ensure proper use of proton pump inhibitors (PPI) and H2 receptor 
antagonists in the patient population. As previously mentioned, the use of these medications has 
been identified as a risk factor of CDI. The results of a study have demonstrated that a large 
proportion (63%) of patients who developed CDI did not present valid indications for usage of 
these medications.32 The use of prophylactic probiotic therapy is another prevention strategy 
currently being explored, but is not recommended at this time, due to mixed results. 
Identification of asymptomatic carriers within patient populations has been explored, but this is 
not recommended as it has not been shown to be effective.   
1.2.5 Diagnosis 
A timely diagnosis of CDI is critical in all situations; especially during outbreaks within the 
healthcare setting. An accurate diagnosis allows for a number of events to take place including 
the initiation of therapy, discontinuation of offending antimicrobials, initiation of contact 
precautions, and adjustment of hand-hygiene practices amongst other institutional procedures 
and protocols. Furthermore, an accurate diagnosis allows for discontinuation of other non-
antimicrobial pharmaceutical agents such as laxatives and stool softeners, which may exacerbate 
symptoms. An accurate diagnosis of CDI is made through a combination of clinical assessments, 
interpretation of results on diagnostic assays, and assessment of risk factors by a qualified 
medical professional. Improper conclusions regarding the presence of CDI can be reached if 
information from clinical assessments, risk factors, or diagnostic assays is excluded.  Therefore, 
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in order for accurate diagnosis to be reached, all relevant medical data regarding possible CDI 
must be considered.   
1.2.5.1 Clinical Assessments 
A number of clinical assessments can cause the clinician to raise the suspicion of possible CDI. 
The gastrointestinal (GI) assessment is one extremely important aspect. It is important to note, 
however, many clinical data which are observed are shared with other gastrointestinal illnesses 
with varying etiology. These include and are not limited to Salmonella, Shigella, Campylobacter, 
Giardia, and Cryptosporidium. The most common presentation in symptomatic infections is 
frequent (>3) watery diarrhea episodes. A characteristic foul odor emanating from the stool is 
often observed by the clinician. Blood and mucus may be observed in the stool in more severe 
instances. Other common symptoms during a GI assessment are abdominal cramps, nausea and 
vomiting. Clinical signs of tenderness with possible abdominal distention which could suggest 
fulminant pseudomembranous colitis. In severe cases, toxic megacolon may be present.  In the 
overall general clinical assessment, a variety of data may be observed. These include varying 
grades of fever; presence of malaise, dehydration, and anorexia. Clinical laboratory assessments 
such as complete blood count with differential, may present results indicating leukocytosis 
defined as leukocyte count greater than 10,000 units/mL, bandemia defined as bands greater than 
5%, and hypoalbunemia defined as albumin level <3 mg/dL. The clinician must differentiate 
clinical presentations as there are other causes of antibiotic-associated diarrhea. These other 
cases of antibiotic-associated diarrhea usually are less severe and often resolve without treatment 
when compared to C. difficile.32,33 
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1.2.5.2 Laboratory Diagnostic Methods 
Diagnostic assays are the major contributory factor in determining whether the causative 
Clostridium difficile agent is present in the patient. A number of types of assays are available and 
are based on different principles (Table 2). Each of these assays varies in the level of their 
effectiveness, possessing different performance characteristics such as values of sensitivity, 
specificity, positive and negative predictive values. In addition, these assays possess their own 
advantages and disadvantages in regards to economics. Timeliness or the overall turnaround time 
to obtain results varies significantly as well. Unfortunately, SHEA and IDSA do not recommend 
a single assay which possesses the attributes of timeliness, cost-effectiveness, and accuracy. 
Therefore, there is a lack of guidance in the medical community as to which assay should be 
used.  In many cases, healthcare institutions must continually evaluate different laboratory 
assays, along with clinical protocols, to determine the best diagnostic approach.  
Two main assays exist to determine the existence of the causative organism, but these 
methods provide limited data on toxin production. The first assay is the anaerobic stool culture 
with subsequent confirmation of toxin production, also known as toxigenic culture.  This assay is 
considered to be a gold standard assay as it is the one of the most sensitive assays available. 
Estimated sensitivity levels are 89-100% based on a meta-analysis.15 However, this particular 
assay lacks timeliness, as it takes 4-7 days to obtain results, and therefore it cannot be practically 
incorporated into patient care settings. Additionally, protocols vary significantly among 
institutions, and therefore, can provide varying accuracy. Most importantly, this assay cannot 
distinguish the different toxin-producing strains.  The Glutamate Dehydrogenase or GDH antigen 
assay detects the metabolic enzyme antigen of C. difficile in a stool sample through antibodies.  
These allow for rapid detection of C. difficile in a matter of hours. However, the positive result 
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GDH antigen assay does not provide information differentiating between a toxigenic and non-
toxigenic strain. For this reason, GDH is used as part of two-step algorithm, where another class 
of assays, which detect toxin, is performed after a positive GDH result. Sensitivity levels for this 
assay are estimated to be 71-100%, while specificity levels are estimated to be 76-98%.14   
 Another group of assays is used to determine the presence of and distinguish toxin 
produced by C. difficile within the stool sample.  The first is the cell culture based cytotoxin 
assay (CCNA).  The principle is based on cytopathic effects (CPE) which are observed when 
stool filtrate is inoculated with a monolayer of cells, usually Human Foreskin Fibroblast. In 
addition to CPE, the neutralization of toxin after incubation of cells with antitoxin is observed in 
a positive culture. Like the toxigenic culture, the disadvantages to this assay are the slow 
turnaround times around 1-2 days.  Furthermore, this assay is sensitive to technique, and 
experienced laboratory technologist personnel are required. Sensitivity levels have been 
estimated to be in the range of 67-86%, and specificity levels are estimated to be 97-100%.14  
Another method, is the enzyme immunoassay (EIA) which detects toxins A and B through the 
use of antibodies. This assay is highly rapid and results can be observed in a matter of hours. 
However, the levels of sensitivity and specificity are highly variable with sensitivity ranging 
from 31-99%, and specificity ranging from 84-100%.14 The Infectious Diseases Society of 
America have taken the position stating this diagnostic approach is suboptimal for routine use, 
due to low sensitivity levels.   
 A final group of newer molecular diagnostic assays, utilize nucleic acid amplification to 
determine presence of C. difficile. These assays are highly promising, with accuracy levels 
surpassing other methods, with the exception of toxigenic culture. One example is the real-time 
polymerase chain reaction (PCR) for qualitative detection of toxigenic Clostridium difficile toxin 
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genes, specifically the tcdB region of the PaLoc. PCR appears to be rapid, sensitive, and specific. 
Sensitivity levels have been observed to be 77-92%, while specificity levels have been observed 
to be 95-99% for one commercial manufacturer’s kit.14 Other newer molecular diagnostic assays 
include isothermal Loop Mediated Isothermal Amplication (iLAMP) technology. Unlike other 
nucleic acid amplification methods, iLAMP targets a region of tcdA. Estimated Sensitivity 
ranges from 83-99% while estimated specificity ranges from 96-100%. The biggest advantage is 
the quick turnaround time with iLAMP technology promising turnaround times in less than one 
hour. 34,35,36 
Regardless of the diagnostic assay used, IDSA and SHEA have made the following 
recommendations. First, testing for C. difficile and its accompanying toxins should be done on 
samples that are unformed diarrheal stool samples. Second, repeating testing on samples is 
usually unhelpful and unproductive and therefore is discouraged.  Additionally, routine testing 
on asymptomatic patients should not receive testing in routine patient care except in cases when 
an epidemiological study is being performed.   
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Table 2. Summary of Clostridium difficile diagnostic methods 
Diagnostic Assay Processing 
Time 
Sensitivity Specificity Advantages Disadvantages 
Toxigenic 
Culture 
Minimum 72 
hours 
89%-100% N/A Gold standard  Does not 
distinguish 
toxins, 
unstandardized 
protocol, not 
timely 
Cell Cytotoxicity 
Neutralization 
Assay 
Minimum 48 
hours 
67%-86% 97%-100% Detects toxin 
producing strains 
Technique 
Sensitive, not 
timely 
Glutamate 
Dehydrogenase 
(GDH) common 
assay 
30-60 minutes 71-100%** 76-98%** Easy to use, 
allows negative 
results to be 
obtained quickly 
Part of two-step 
regimen to 
detect toxigenic 
strains 
Enzyme 
Immunoassay 
(EIA) 
2 hours 31-99%** 84-100%** Easy to use, timely Low sensitivity 
Real-Time 
Polymerase 
Chain Reaction 
(RT-PCR)* 
3 hours 77-92%** 95-99%** High sensitivity and 
specificity superior 
to other methods, 
timely 
Unfavorable, 
economics   
Isothermal loop 
mediated 
amplification 
(iLAMP) 
15-30 minutes 83-99%*** 96-100%*** Timely, high 
sensitivity and 
specificity** 
Requires 
proprietary 
instrumentation 
Endoscopy 1-2 hours 51% N/A Allows for 
visualization 
pseudomembranes 
Low sensitivity 
* RT-PCR sensitivity and specificity levels apply to Prodesse ProGastro™ assay  
**Sensitivity and specificity based on a meta-analysis of comparisons utilizing various reference 
standards including toxigenic culture, CCNA or a composite gold standard.14 
 
***Sensitivity and specificity based on a meta-analysis utilizing toxigenic culture as a 
reference standard34.35,36 
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1.2.5.3 Other Diagnostic Methods 
Other diagnostic methods are sometimes used in the overall diagnosis of CDI including 
endoscopy to observe presence of pseudomembranes and radiographic methods such as 
abdominal computerized tomography (CT) scans to observe colonic thickening and free air 
which are characteristic of CDI. However, sensitivity and specificity are not sufficient as 
compared to laboratory diagnostic assays with estimated sensitivity levels of 51% for endoscopy. 
Therefore, these diagnostic tools are not accurate and should not be relied upon to make a 
definitive diagnosis of CDI. 
 
1.3 PUBLIC HEATH SIGNIFICANCE 
The public health significance of Clostridium difficile infection is demonstrated through 
increased incidence, mortality rates, and attributable healthcare costs. Furthermore, populations 
previously at low risk are increasingly becoming vulnerable. The public health impact is 
forecasted to increase further. One problem encountered with quantifying CDI is the varying 
requirements for reporting of CDI. At a national level, surveillance of CDI is a patient safety 
component of the National Healthcare Safety Network (NHSN) overseen by the CDC. The 
NHSN is internet based surveillance system with voluntary reporting by healthcare institutions. 
Only institutions from 27 states have reported to this database as of 2010. Additionally, reporting 
requirements to territorial and state health departments on the incidence of hospital acquired 
infections vary by state. However, more surveillance programs are incorporating CDI. For 
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instance, CDI is also part of the emerging infections program (EIP) which is part of the CDC, 
however, data from this program has not been released at this time.  Because of this, the ability 
to obtain complete and truly accurate surveillance data on CDI at the national level is hampered.  
Nevertheless, there is evidence to support an increase in the public health burden through various 
initiatives. These include initiatives and campaigns through insurance companies, and state 
health departments. Based on current data, there is an interest in combating this preventable 
nosocomial infection. 
According to the Healthcare Cost and Utilization Project (HCUP), part of the Agency for 
Healthcare Research and Quality (AHRQ), an increasing trend has been observed in the 
incidence CDI being classified as a primary or secondary diagnosis during hospital stays. There 
has been an increase from 85,700 hospital stays in 1993 to 336,600 hospital stays in 2009 (Figure 
4). Restated, there has been an increase from 86,000 hospital discharges involving CDI in 1993 
to 337,000 hospital discharges in 2009.  Elderly patients over the age of 85 years, who are among 
highest at risk are disproportionately affected and have had incidence rates increase to 1,089 per 
100,000 patients. This contrasts to all other age groups with a combined rate of 603 per 100,000 
patients.37 Additionally, peripartum women, previously at low risk have seen infection rates 
increase.5 The number of deaths due to CDI has increased over time as well. During the time 
period 2000-2007 deaths related to CDI have increased 400% (Figure 5). As of 2010, 14,000 
deaths were attributable to this disease.38 Ninety percent of those deaths occurred in individuals 
65 and older. According to the CDC, comparing the time periods 1991-1997 and 2004-2009, 
there has been a 12 fold increase in incidence of disease in children from 2.6 cases per 100,000 
to 32.6 cases per 100,000.39   
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Figure 4. Trends in hospital admissions from 1993-2009, with a primary or 
secondary Clostridium difficile infection (CDI) (Agency for Healthcare Research and 
Quality) 
 
Figure 5. Age-Adjusted rates of deaths attributable to CDI (primary cause) (CDC 
National Center for Health Statistics, 2012) 
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Economic costs attributable to CDI are estimated to be $8.2 billion annually as of 2009. 
Because of the disproportionate effect on the elderly population, Medicare is more financially 
impacted bearing 67.9 percent of all C. difficile financial costs covered.  The average cost for a 
hospital stay attributable to CDI is $24,400 as of 2009. Considering the high potential for relapse 
the economic costs have a potential to increase further. Additionally, not taking into account 
indirect economic costs, such as loss of economic productivity, total economic costs could be 
much higher.33        
 The increased public health burden is partly attributable to newer, more virulent 
Clostridium difficile strains, mainly the group BI restriction endonuclease, North American 
pulse-field-type 1 characterized by pulse-field gel electrophoresis and ribotype 027 
(BI/NAP1/027) strain. This strain is characterized by possession of CDT binary toxin and 18 bp 
deletion of the negative regulator tcdC in the PaLoc. This strain has increased in prevalence due 
to the increased use of fluoroquinolones.  This new more virulent strain as of 2010 has spread to 
40 states in the US, seven Canadian providences, parts of Asia, Europe, and England. Notable 
outbreaks included severe outbreak of disease in the University of Pittsburgh Medical Center 
starting January 2000 ending April 2001, and severe disease outbreaks in hospitals throughout 
Quebec Canada starting in 2002 and ending 2006.5, 26 
The current 2013 national prevention target set by the Department of Health and Human 
services is a 30% reduction in hospitalizations with primary or secondary healthcare associated 
CDI based on the 2008 baseline measurement of 11.7 hospitalizations diagnoses per 1,000 
discharges.40 
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2.0  THESIS AIMS 
There are multiple approaches to achieve reduction of C. difficile infection. The main approaches 
include continual research in prevention strategies, treatment strategies, and diagnostics. 
Arguably, the most important approach is through the continual evaluation and adjustment of 
current diagnostic capabilities and protocols in the healthcare institution. This strategy is crucial 
as accurate, timely, and cost-effective diagnostics allow for effective surveillance, especially for 
reporting to state and federal disease surveillance programs. Diagnostics allow for the 
identification of any trends in the incidence of disease. Without identification of disease trends, 
the case for a focus on disease prevention and development of better therapies cannot be 
supported.  Furthermore, improving diagnostics allow for quicker initiation of treatment, and 
allows for isolation and contact procedures to be implemented. Therefore, continual evaluation 
and necessary modification of current diagnostic protocols is essential. Because of a lack of 
general consensus on a single assay which is timely, accurate, cost-effective within the medical 
community, it is up to the medical institution to routinely evaluate current practices and compare 
to other currently available diagnostic methods to determine a routine assay which provides the 
best fit for the institution and the patient. 
Numerous research studies involving the comparison of commercially available 
Clostridium difficile diagnostic assay kits have been published. While this is the case, many of 
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these studies have limitations. Few studies have used the current gold standard within the 
medical community, anaerobic stool culture for toxin-producing Clostridium difficile (toxigenic 
culture), rather these studies have used either CCNA or a composite gold standard, consisting of 
positive result on multiple assays within the study as a gold standard.41,42,43 Furthermore, the 
most important deficiency of these and many other studies is lack of incorporation of clinical 
data to further assess the assay.   A diagnosis of CDI is made in conjunction with clinical data, 
such as patient symptoms, and assessment of risk factors.  Asymptomatic CDI carriers could be 
detected with their diarrhea being caused by other factors such as laxative and stool softener use, 
or other gastrointestinal infection. If the clinician did not take these clinical aspects into account, 
it would cause the wrong conclusion to be made about performance characteristics of the assay 
being evaluated.  Few studies have incorporated clinical data, and the need for further studies is 
therefore warranted. 
Understanding shortcomings of the previous studies presents opportunities for 
improvement in which the study design corrects errors to perform an effective comparison of 
Clostridium difficile assays providing better data for the medical institution and the medical 
community which translates to better clinical care and overall outcomes. 
The purpose of this research study was to evaluate the performance characteristics 
(sensitivity, specificity, positive predictive value, and negative predictive value) of existing C. 
difficile assays (e.g. GDH, EIA CCNA, anaerobic toxigenic culture) and of newer generation 
molecular  diagnostic assays (e.g. RT-PCR, iLAMP) through a comparative evaluation utilizing 
semi-quantitative toxigenic culture as a reference standard. Further, there is an interest to 
determine if it is possible to refine the estimate of the performance characteristics through the 
incorporation of risk factors, laboratory data and clinical symptoms from the medical record of 
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patients who undergo testing for Clostridium difficile. Based on the current literature, we 
hypothesize that performance characteristics of newer generation molecular assays will be better 
than their older counterparts. Additionally, we hypothesize that the performance characteristics 
of each assay can be refined through the through the use of clinical data. Lastly, we hypothesize 
that discrepant positive results on molecular nucleic acid amplification assays are  asymptomatic 
carriers.  
This research study is divided into three specific aims: 
AIM #1: Explore performance characteristics of various diagnostic assays for 
CDI using toxigenic culture as a reference standard. 
AIM #2: Explore potential refinement of performance characteristics through 
incorporation of clinical data into the results. 
AIM #3: Explore potential associations between individual risk factors, 
symptoms and results on semi-quantitative toxigenic culture. 
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3.0  MATERIALS AND METHODS 
3.1 STUDY DESIGN 
 
The study design was composed of two components, a lab-based component which involved 
collection and testing of patient stool samples, and an epidemiologic component which involved 
retrospective review of medical records to review patient symptoms and risk factors. The 
University of Pittsburgh Institutional Review Board reviewed and approved the study protocol. 
During the study period-November 2011 through February 2012- 524 consecutive stool samples 
were tested from 427 patients using specimens from tests ordered by physicians for Clostridium 
difficile stool toxin. Samples were collected from either UPMC Presbyterian or UPMC 
Shadyside campuses including their respective hospital-based outpatient clinics and were sent to 
the clinical microbiology laboratory at UPMC Presbyterian.  Specimens were collected daily 
Sunday-Thursday and stored overnight at 4°C for further processing.  Only stool specimens 
which were unformed and had total volume greater than or equal to 20cc were included which 
ensured enough volume for all five diagnostic assays within the study. Physicians were not made 
aware of the results of assays other than the existing CCNA assay routinely reported. 
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3.2 DIAGNOSTIC ASSAYS 
 
3.2.1 Anaerobic Toxigenic culture with subsequent confirmation of toxin production 
(toxigenic culture) 
Toxigenic culture was performed to determine the presence of either non-toxigenic or toxigenic 
C. difficile. In a biological safety cabinet, 10 µl of stool was planted on cefoxitin cycloserine 
mannitol agar with 0.1% taurocholic acid and lysozyme (CCMA-TAL) using four-quadrant 
technique. An additional 10 µl of stool was broth-enriched in 5 ml cefoxitin cycloserine mannitol 
broth with taurocholate and lysozyme (CCMB-TAL) (Anaerobe Systems, Morgan Hill, CA). 
CCMA-TAL and CCMB-TAL media were transferred after inoculation to an anaerobic chamber 
(Coy Laboratory Products, Grass Lake, MI) and incubated at 37°C for three days. C. difficile 
was identified by morphology and yellow fermentation on CCMA-TAL and characterized as 
rare, light, moderate, or heavy growth depending on the number of quadrants in which it 
appeared.  If the no C. difficile was observed on the directly plated specimen, the CCMB-TAL 
broth-enrichment specimen was sub-cultured to trypticase soy agar with 5% sheep blood (SBA, 
Becton Dickinson, Franklin Lakes, NJ) if the broth showed a color shift from red to yellow. All 
suspected C. difficile colonies were sub-cultured to SBA plates to ensure purity and confirmed as 
C. difficile using L-prolineaminopeptidase activity (PRO disk, Remel, Lenexa, KS). Isolates 
were store in chopped meat broth (Anaerobe Systems) and regrowtn on BHIYT plates for DNA 
extraction by the NucliSens easyMag system (Biomerieux, Durham, NC). Isolates underwent 
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tdcC and MLVA genotyping. All isolates with a tcdC genotype were inferred to be toxigenic. 
Any isolate with no amplification of tcdC was tested with lok1/lok3 primer set to confirm that it 
was non-toxigenic C. difficile. 
  
3.2.2 Glutamate Dehydrogenase assay (GDH) and Enzyme Immunoassay (EIA) assay 
Stools were assayed for the glutamate dehydrogenase antigen using the Alere™ QUIK CHEK 
COMPLETE (Techlab, Blacksburg, VA) following manufacturer’s instructions. In addition to 
determining the presence of GDH common antigen, the assay includes an enzyme linked 
immunoassay for toxins A and B. Accordingly this kit gave two separate results, one for GDH 
and one for EIA.   
 
3.2.3 Cell cytotoxicity neutralization assay (CCNA) 
Stool samples were stored at 2-8°C and processed within 24 hours of collection to ensure 
integrity of toxin within the sample. A 1 ml fecal sample aliquot was centrifuged at 10,000g for 
10 minutes and supernatant was collected, filtered using a 0.22µm syringe filter (Millipore, 
Billerica, MA). Supernatant was diluted to 1:40 with M4 medium then added to human foreskin 
fibroblast (Hs27, Diagnostic Hybrids, Athens OH) in a 96 well plate. A control was prepared 
with specimen supernatant and 50ul of C. difficile goat derived antitoxin (Techlab Inc., 
Blacksburg, VA). After incubation at 37°C for 24 hours, cells where checked for cytopathic 
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effects which was defined as CPE in 50% or greater of the monolayer and anti-toxin 
confirmation defined by no cytopathic effects in control cells incubated with C. difficile 
antitoxin. This test is the current clinical test at UPMC Presbyterian and was reported in the 
clinical record. 
3.3 MOLECULAR DIAGNOSTIC ASSAYS 
 
3.3.1 Isothermal loop mediated amplication (iLAMP) 
The Meridian Illumigene™ molecular diagnostic assay (Meridian Bioscience, Cincinnati, OH) 
which utilized isothermal loop mediated amplification was utilized as one means of molecular 
diagnostics for C. difficile.  The system targets the tcdA gene for amplification.  The assay was 
performed as directed by the manufacturer. The results of the assay were read using the 
illumipro-10 instrument (Meridian Bioscience, Cincinnati, OH) and results were interpreted 
according to manufacturer’s protocol as positive, negative, or indeterminate. 
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3.3.2 Real-time polymerase chain reaction (RT-PCR) 
The Prodesse Progastro Cd real-time polymerase chain reaction (RT-PCR) assay (Gen-Probe 
Prodesse, Waukesha, WI) targets and amplifies the Clostridium difficile toxin B gene (tcdB). The 
RT-PCR assay was modified to run on ABI 7500 Fast thermal cycler (Applied Biosystems, 
Foster City, CA). The marker of Clostridium difficile burden was the cycle threshold value (Ct). 
It is defined as the PCR cycle where enough amplification of the nucleic acid amplification has 
occurred to generate a fluorescent signal which can be detected.  In our study, a Ct value ≤35 
was considered positive. 
3.4 RETROSPECTIVE CHART REVIEW OF CLINICAL DATA 
A retrospective chart review was conducted on a subset of the medical records of 427 patients in 
the study who had discrepant results on iLAMP, PCR, and CCNA assays. The medical records 
were accessed by an honest broker and anonymized. Demographic data, history and physical 
data, laboratory data, radiology reports, progress reports, operative and pathology reports, 
pharmacological data, and microbiology reports were reviewed.  
A CDI likelihood score was assigned based on a number of factors found in previous 
studies to be associated with CDI in case-control studies (Table 3).44 Each factor was assigned a 
numerical value and the sum of applicable numerical values determined the likelihood score. 
Factors which favored CDI included prior history of CDI, prior outpatient and inpatient medical 
exposure over the course of 12 weeks, medical co-morbidities, intubation, antimicrobial 
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exposure in previous 12 weeks, H2 and PPI use in prior 12 weeks were risk factors which favored 
CDI. Symptoms which favored CDI diagnosis included diarrhea, abdominal pain, fever greater 
than 37.9°C, elevated white blood cell count, and hypoalbuminemia. Other clinical assessments 
which favored CDI include colonoscopic evidence of pseudomembranous colitis, and 
pathological and radiological evidence suggesting colitis. However, clinical features which 
suggested alternative diagnoses were considered. These included a diagnosis of other 
gastrointestinal illnesses with infectious origins, use of laxatives, lack of diarrhea/presence of 
formed stools/constipation accompanying positive Clostridium difficile toxin result. Presence of 
alternative pathologies involving the gastrointestinal tract such as Crohn’s disease, ulcerative 
colitis, and irritable bowel syndrome were assigned negative numerical values and lowered the 
CDI likelihood score. 
Measurements of medical co-morbidities involved the use of Horn’s index. The Horn’s 
index is a four-tiered index of disease severity and is assigned based on clinical judgment. 
Previous studies have incorporated the Horn index to predict C. difficile outcomes. Horn scores 
of 1 indicate typically a single mild acute illness with higher tiered scores indicating numerous 
chronic diseases with the potential for fatal outcomes.  
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Figure 6. Summary Diagram of Study Design. 
Semi-quantitative toxigenic culture was performed on the first 427 non-duplicate stool samples. 
If C. difficile growth was not observed, the patient was classified as not having CDI. If growth of 
C. difficile was observed, genotyping was performed. If an isolate possessed a tdcC genotype the 
strain was inferred to be toxigenic. Otherwise the C. difficile sample was not considered 
toxigenic and the patient was considered CDI negative. These results were used as a basis for 
evaluation of the other assays A retrospective chart evaluation was performed on the discrepant 
results with positive and negative controls.  
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Table 3. Scoring criteria for Clostridium difficile likelihood score 
Features favoring CDI Points Comments 
Prior history of CDI 1  
Prior outpatient healthcare exposure (<12 weeks) 1 Only  
(highest-
scoring) 
category 
per patient 
Prior inpatient (hospital or Skilled Nursing Facility) exposure (<12 
weeks prior) with length of stay  <1 week 
1 
Prior inpatient (hospital or Skilled Nursing Facility) exposure (<12 
weeks prior) with length of stay 1-2 weeks 
2 
Prior inpatient (hospital or Skilled Nursing Facility) exposure (<12 
weeks prior) with length of stay >2weeks 
3 
Medical co-morbidity index: Horn score of 1 0  Only one 
score Medical co-morbidity index: Horn score of 2 1 
Medical co-morbidity index: Horn score of 3 2 
Medical co-morbidity index: Horn score of 4 3 
Tube feedings (nasogastric, gastric, or duodenal) 1  
Diarrhea (any mention in notes -5 to +5 days from 1st CDIFT sent) 2  
Abdominal pain/cramping 2  
Fever > 37.9 °C (-5 to +5 days from first CDIFT sent) 1  
Peripheral WBC count >10K (max +/- 5 days from 1st CDIFT) 1  Only 
highest 
score 
Peripheral WBC count >15K (max +/- 5 days from 1st CDIFT) 2 
Peripheral WBC count >20K/Band % >5%  
(max +/- 5 days from 1st CDIFT) 
3 
Colonoscopic evidence of pseudomembranous colitis 2  
Albumin < 3 mg/dL (min +/- 5 days from 1st CDIFT) 2  
Antimicrobial exposure in 12 weeks prior to testing: 
quinolones/ceftriaxone/clindamycin 
3  
Antimicrobial exposure in 12 weeks prior to testing: all other antibiotics 2  
Pathological evidence of pseudomembranous colitis 2  
Radiological evidence of colitis (colonic thickening, free air, 
pneumatosis coli) 
2  
H2 blocker or PPI use in 12 weeks prior to testing 1  
Features favoring alternative diagnosis 
Diagnosis of alternate infection (Salmonella, Shigella, Campylobacter, 
Giardia, Cryptosporidium, other OI in HIV+ patient) 
- 15  
Use of laxatives (colace, senna, PEG, Mg-citrate, lactulose) +/- 5 days 
from CDIFT testing 
-5  
Mention of formed stools/constipation/”no diarrhea” in clinical notes -3 
to 0 days from first positive CDIFT 
-5  
Alternative pathological diagnosis (e.g. ischemic colitis) -10  
Mention of Crohn’s disease, ulcerative colitis, Irritable bowel syndrome -1  
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3.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using SAS 9.3 (SAS Institute Inc, Cary, NC). 95% confidence 
intervals for performance characteristics of tests were generated using Clopper-Pearson exact 
binomial intervals.   
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4.0  RESULTS 
4.1 AIM #1: EXPLORE PERFORMANCE CHARACTERISTICS OF VARIOUS 
DIAGNOSTIC ASSAYS FOR CDI USING TOXIGENIC CULTURE AS A REFERENCE 
STANDARD 
 
4.1.1 Toxigenic Culture 
The current gold standard assay, toxigenic culture, was performed on the first non-duplicate 
sample submitted from all 427 patients, out of 524 samples within the study period. Results from 
the toxigenic culture were categorized semi-quantitatively as being a non-toxigenic or toxigenic 
strain (Table 4). A semi-quantitative result of C. difficile from broth only indicated growth of C. 
difficile in CCMB-TAL broth only.  Rare, light, moderate, and heavy C. difficile result indicated 
growth in one, two, three, or all four quadrants of the CCMA-TAL directly plated specimen, 
respectively. Three hundred thirty-nine samples yielded no C. difficile when toxigenic culture 
was performed.  Growth of non-toxigenic strains of C. difficile occurred in 31 samples and 
growth of C. difficile toxigenic strains were present in 57 patient samples. These 57 patients with 
toxigenic C. difficile served as the primary focus for further evaluation throughout the study. For 
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purposes of this study, the 339 specimens with no growth of C. difficile and 31 non-toxigenic 
results were defined as negative by the gold standard.  
 
 
 
Table 4. Classification of Toxigenic culture by semi-quantitative growth and toxin 
production 
 
Semi-quantitative result Non-toxigenic Toxigenic 
No C. difficile 339 
C. difficile from broth only 9 6 
Rare C. difficile 5 22 
Light C. difficile 5 5 
Moderate C. difficile 2 7 
Heavy C. difficile 10 17 
Total 31 57 
 
 
   
36 
 
4.1.2 Performance characteristics of Enzyme Immunoassay (EIA) defined by toxigenic 
culture 
An evaluation of EIA based on the toxigenic culture defining true disease status was performed.  
Out of 427 patient samples of which both EIA assay and toxigenic culture were performed, there 
were 370 concordant negative results, and 16 concordant positive results (Table 5).  The 
performance characteristics of the EIA based assay demonstrated low sensitivity. The sensitivity 
of the EIA assay was found to be lower than previously reported results at 28.1%, 95% CI (17.0, 
41.6). The specificity of the EIA assay was excellent and was observed to be 100%, 95% CI 
(99.0, 100.0).  Additionally, the positive predictive value was excellent and found to be 100%, 
95% CI (79.4, 100.0) while the negative predictive value was found to be 90%, 95% CI (86.7, 
92.6) (Tables 5 and 10). 
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Table 5. Performance characteristics of Enzyme Immunoassay defined by toxigenic 
culture 
 
Alere™ QUIK CHECK EIA 
Toxigenic Culture Positive Negative Total 
Positive 16 41 57 
Negative 0 370 370 
Total 16 411 427 
  95% CI 
Sensitivity 16/57=28.1% (17.0-41.6) 
Specificity 370/370=100% (99.0-100.0) 
Positive Predictive Value 16/16=100% (79.4-100.0) 
Negative Predictive Value 370/411=90.0% (86.7-92.6) 
 
4.1.3 Performance characteristics of cell cytotoxicity neutralization assay defined by 
toxigenic culture 
Of 427 samples, there were 26 concordant positive results and 367 concordant negative results 
based on the toxigenic culture defining true disease status (Table 6). Sensitivity of the CCNA 
assay was observed to be below previously reported values at 45.6%, 95% CI (32.4, 59.3). 
Specificity was excellent with a high rate at 99.2%, 95% CI (97.7, 99.8). Positive predictive 
value was observed to be 89.7%, 95% CI (72.7, 97.8) and negative predictive value was 
observed to be 92.2%, 95% CI (89.1, 94.7) (Tables 6 and 10). 
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Table 6. Performance characteristics of cell cytotoxicity assay (CCNA) defined by 
toxigenic culture 
 
Cytotoxicity assay (CCNA) 
Toxigenic Culture Positive Negative Total 
Positive 26 31 57 
Negative  3 367 370 
Total 29 398 427 
  95% CI 
Sensitivity 26/57=45.6% (32.4-59.3) 
Specificity 367/370=99.2% (97.7-99.8) 
Positive Predictive Value 26/29=89.7% (72.7-97.8) 
Negative Predictive Value 367/398=92.2% (89.1-94.7) 
4.1.4 Performance characteristics of isothermal loop mediated amplification (iLAMP) 
assay defined by toxigenic culture 
An evaluation of a newer-generation iLAMP molecular nucleic acid amplification assay, 
Meridian illumigene™, was performed, with toxigenic culture defining presence of C. difficile 
(Table 7). Of 427 samples, there were 35 concordant positive results and 366 concordant 
negative results.  Sensitivity was found to be 61.4%, 95% CI (47.5, 74.0).  Specificity on the 
other hand, was found to be in agreement with previously reported values with a rate of 98.9% , 
95% CI(97.7, 99.7). Positive predictive value was found to be 89.7%, 95% CI (75.8, 97.1). The 
negative predictive values was found to be 94.3%, 95% CI (91.5, 96.4) (Tables 7 and 10).  
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Table 7. Performance characteristics of isothermal loop mediated amplification 
(iLAMP) assay defined by toxigenic culture 
Isothermal loop mediated amplification (iLAMP) 
Toxigenic Culture Positive Negative Total 
Positive 35 22 57 
Negative  4 366 370 
Total 39 388 427 
  95% CI 
Sensitivity 35/57=61.4% (47.5-74.0) 
Specificity 366/370=98.9% (97.7-99.7) 
Positive Predictive Value 35/39=89.7% (75.8-97.1) 
Negative Predictive Value 366/388=94.3% (91.5-96.4) 
4.1.5 Performance characteristics of Prodesse Progastro Cd™ Real-Time Polymerase 
Chain Reaction (RT-PCR) assay defined by toxigenic culture 
An evaluation of a second molecular nucleic acid amplification assay, RT-PCR, was performed 
specifically the Prodesse Progastro Cd™ assay. This assay targeted the tcdB gene. As with all 
other evaluations, toxigenic culture defined presence of C. difficile (Table 8). All Ct values were 
considered positive. Of 427 samples, there were 35 concordant positive results and 366 
concordant negative results.  Sensitivity was found to be 57.9%, 95% CI (44.2, 70.9), in the 
range of previously reported sensitivity values.  Specificity also was found to be in the range of 
previously reported values with 99.7%, 95% CI (98.5, 100). Positive predictive value was found 
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to be 97.1%, 95% CI (84.7, 99.9). The negative predictive value were found to be 93.9%, 95% 
CI (91.1, 96.1) (Tables 8 and 10). 
 
Table 8. Performance characteristics of Prodesse Progastro Cd™ Real-Time 
Polymerase Chain Reaction (RT-PCR) defined by toxigenic culture 
Prodesse Progastro Cd™ RT-PCR 
Toxigenic Culture Positive Negative Total 
Positive 33 24 57 
Negative  1 369 370 
Total 34 393 427 
  95% CI 
Sensitivity 33/57=57.9% (44.2-70.9) 
Specificity 369/370=99.7% (98.5-100) 
Positive Predictive Value 33/34=97.1% (84.7-99.9) 
Negative Predictive Value 369/393=93.9% (91.1-96.1) 
 
4.1.6 Performance characteristics of Glutamate Dehydrogenase (GDH) assay defined by 
toxigenic culture 
An evaluation of an assay the common metabolic enzyme antigen, Glutamate Dehydrogenase 
(GDH), specifically the Alere™ QUIK CHECK COMPLETE assay was performed. As with all 
other evaluations, toxigenic culture defined presence of C. difficile (Table 9). Of 427 samples, 
there were 45 concordant positive results and 347 concordant negative results.  Sensitivity was 
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found to be 79.0%, 95% CI (66.1, 88.6), in the range of previously reported sensitivity values.  
Specificity also was found to be in the range of previously reported values at 93.8%, 95% CI 
(90.8, 96.0). Positive predictive value was found to be 66.2%, 95% CI (53.7, 77.2). The negative 
predictive values were found to be 96.7%, 95% CI (94.2, 98.3) (Tables 9 and 10). 
 
Table 9. Performance characteristics of Glutamate Dehydrogenase (GDH) defined 
by toxigenic culture 
Alere™ QUIK CHECK COMPLETE Glutamate Dehydrogenase (GDH) 
Toxigenic Culture Positive Negative Total 
Positive 45 12 57 
Negative  23 347 370 
Total 68 359 427 
  95% CI 
Sensitivity 45/57=79.0% (66.1-88.6) 
Specificity 347/370=93.8% (90.8-96.0) 
Positive Predictive Value 45/68=66.2% (53.7-77.2) 
Negative Predictive Value 347/359=96.7% (94.2-98.3) 
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Table 10. Performance characteristics of all assays evaluated defined by toxigenic 
culture 
  
CCNA 
 
GDH 
 
EIA 
 
RT-PCR 
 
iLAMP 
Sensitivity 45.6% 79.0% 28.1% 57.9% 61.4% 
Specificity 99.2% 93.8% 100% 99.7% 98.9% 
Positive 
Predictive Value 
89.7% 66.2% 100% 97.1% 89.7% 
Negative 
Predictive Value 
92.2% 96.7% 90.0% 93.9% 94.3% 
 
4.2 AIM #2 EXPLORE POTENTIAL REFINEMENT OF PERFORMANCE 
CHARACTERISTICS THROUGH INCORPORATION OF CLINICAL DATA  
In order to investigate the hypothesis that the new molecular assays are detecting patients who 
are asymptomatically colonized, the charts of all patients with discrepant results were reviewed. 
Serving as a negative and positive control, the charts of patients with concordant positive results 
(iLAMP, PCR, and CCNA) charts and concordant negative charts were reviewed. Concordant 
negative results had toxigenic culture results stratified to examine the C. difficile likelihood 
score. This was done by examining the mean, median and standard deviation of the assigned C. 
difficile likelihood score among these groups. Risk factors for CDI, defined as presence of 
diarrhea, use of antibiotics, and inpatient exposures were also examined for the same patients. 
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These factors are considered by many as the sine qua non of CDI and therefore are of interest.  
Between all nine groups, it was found that there was no significant difference between the mean 
or median C. difficile likelihood scores (Table 11). Furthermore, a high proportion of patients 
had all three factors for disease, particularly antibiotics, with exceptions being group five which 
had lacked diarrhea according to chart review although having unformed stool samples for 
inclusion within the study. Specimens being submitted for CDI testing at this clinical 
microbiology laboratory have a high likelihood of CDI, and therefore negative tests within the 
discrepant categories are highly likely to represent false negative results.   
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Table 11. Comparison of C. difficile likelihood score and patient factors between discrepant results 
Group N=                     Combinations of Results 
Prodesse     Illumigene™               Toxigenic 
RT-PCR         iLAMP           CCNA        Culture 
                                                              
C.difficile Likelihood Score  
                             Standard 
Mean   Median  Deviation 
Patient Risk Factors 
Diarrhea    Antibiotics     Inpatient         
None 
                                         Exposure 
1 11 Positive Positive Positive N/A 13 13.5 2.5 82% 90% 82% 0% 
2 17 Positive Positive Negative N/A 8.8 8 3.8 76% 76% 65% 0% 
3 4 Positive Negative Positive N/A 11 10 3.1 75% 100% 75% 0% 
4 3 Positive Negative Negative N/A 9.3 9 5.5 66% 100% 33% 0% 
5 1 Negative Positive Positive N/A 9 9 N/A 0% 100% 100% 0% 
6 2 Negative Positive Negative N/A 12 12 5.2 100% 100% 100% 0% 
7 5 Negative Negative Positive N/A 10 11 4 80% 80% 60% 0% 
8 4 Negative Negative Negative Positive 9.4 10 2.6 100% 100% 75% 0 
9 9 Negative Negative Negative Negative 8.9 9.5 5.0 60% 80% 60% 10% 
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4.3 AIM#3 EXPLORE POTENTIAL ASSOCIATIONS BETWEEN RISK FACTORS, 
SYMPTOMS, AND RESULTS ON SEMI-QUANTITATIVE TOXIGENIC CULTURE 
The final analysis explored a potential association between semi-quantitative results on toxigenic 
culture and clinical characteristics, defined by the C. difficile likelihood score and individual risk 
factors. A potential association between positive results on toxin detecting assays and semi-
quantitative toxigenic culture was investigated (Tables 12 and 13). No observable trend was 
observed between results of semi-quantitative culture and the percentage of positive results on 
any assay. Additionally, there was no correlation between the frequency of individual factors and 
results on semi-quantitative culture (Table 13). Further, there was no association between the 
factors and results on semi-quantitative culture. A large proportion of patients are observed in 
almost all cases to possess all three exposures, including those who tested negative on the semi-
quantitative assay.  
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Table 12. Comparison of positive results on toxin detecting assays and C. difficile 
likelihood scores between semi-quantitative result 
Semi-
quantitative 
result 
N C. difficile likelihood score 
Mean    Median   Standard 
                              Deviation 
Positive Results 
                                               Molecular 
    EIA               CCNA                iLAMP           Prodesse 
                                                                       RT-PCR 
(heavy) M 12.5 12.5 2.5 5/12.5= 42% 7/12.5=58% 10/12.5=83% 10/12.5=83% 
(moderate) 3 12 13 3.6 2/3= 66% 3/3= 100% 2/3= 66% 2/3= 66% 
(light) 5 9.8 9 2.6 0% 2/5= 40% 4/5= 80% 5/5= 100% 
(rare) 14 8.9 8 5.0 3/14= 21% 5/14=35.7% 9/14= 64% 10/14= 71% 
(broth only) 4 8 8.5 3.6 0% 1/4= 25% 2/4= 50% 3/4= 75% 
(negative) 13 9.2 9 5.9 0% 1/13=7.6% 1/13= 7.6% 1/13=7.6% 
 
Table 13. Comparison of rates of patient exposures, symptoms and results on Semi-
quantitative culture 
Semi-
quantitative 
result 
N Patient Factors 
Diarrhea            Antibiotics          Inpatient           None 
(heavy) 12 92% 100% 92% 0% 
(moderate) 3 66% 100% 66% 0% 
(light) 5 100% 60% 80% 0% 
(rare) 14 79% 79% 43% 0% 
(broth only) 4 100% 100% 75% 0% 
(negative) 13 54% 85% 62% 0% 
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5.0  DISCUSSION 
Clostridium difficile is a problematic infection routinely encountered by healthcare professionals 
and patients in the hospital setting. Once a rare, nuisance infection with few severe outcomes, the 
disease is increasingly affecting a variety of populations due to changes in risk factors and 
clinical practices. These include the indiscriminate use of antimicrobials, proton pump 
inhibitor/H2 blocker, and poor infection control practices.  
At the same time, there are other issues with C. difficile surveillance and diagnosis.  
There is limited surveillance data as reporting is voluntary and state laws vary in regards to 
reporting requirements. Only recently, other countries have started to establish surveillance 
programs for C. difficile, mainly in Western Europe as a consequence of increasing incidence.  
Potentially hampering the surveillance is the medical community lacking a cost-effective, rapid, 
and perhaps most importantly, accurate assay to help the clinician make the diagnosis of 
Clostridium difficile. Having a rapid assay allows for treatment initiation at an earlier time, 
leading to better outcomes, as the patient will not be allowed to have disease progress. Having an 
accurate assay, particularly one with high sensitivity, ensures, that patients are appropriately 
treated and isolated within hospital, potentially translating to fewer patients shedding spores in 
the healthcare setting. Ensuring the assay possesses high specificity is of importance as well. The 
greater number of false positive patients leads to increased use of antimicrobials, leading 
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increased treatment costs, and potential for development of other organisms resistant to the 
antimicrobial agents, particularly vancomycin.   
 The purpose of this study was to examine the performance characteristics independently 
of the other attributes of the assay, mainly the processing time, and cost-effectiveness. While 
these attributes are of importance to other parties including the patient and the medical 
institution, the results of this study will be used in conjunction with those attributes to determine 
which assay is best for our medical institution.  A notable aspect of this study was its 
incorporation of clinical data through development of a C. difficile likelihood score in an attempt 
to refine the performance characteristics of assays, in particular the newer molecular assays 
which employ nucleic acid amplification.  Additionally, there was an interest in determining if 
there was relationship between semi-quantitative result on a toxigenic culture and C. difficile 
likelihood score as well as individual clinical factors. 
 When examining the comparison of assays without clinical data, it was found that 
enzyme immunoassay had poor sensitivity, which supports the recommendation made by SHEA 
and IDSA that this as a method as less desirable. It was also found that the CCNA had high 
specificity and positive predictive value, but its sensitivity and negative predictive values were 
surprisingly low compared to some prior studies. One reason for this observation is the 
increasing skill of labs performing toxigenic culture, which included broth enrichment which 
may increase sensitivity. The GDH common antigen assay yielded fair performance 
characteristics. However, this assay did not have a sufficient negative predictive value to serve as 
a good screening test. Neither of the two molecular assays (Prodesse Progastro™ RT-PCR and 
illumigene™ iLAMP) yielded performance characteristics superior to the other, and compared to 
the gold standard toxigenic culture they miss up to 40% of patients with toxin-producing C. 
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difficile in their stools. However, both methods are superior to the currently used CCNA assay. 
Applying these results to clinical practice, treating CDI in context of a high pre-test probability is 
advisable based on these results. When interpreting the results of these molecular assays it is 
important to note that the gene target of each of these individual assays is different. The Prodesse 
Progastro assay utilizes the tcdB gene, while the illumigene iLAMP amplifies the tcdA gene. At 
the current time the most prevalent strains are tcdA+/tcdB+, with the small minority of strains 
possessing tcdA-/tcdB+ genotype. Therefore, continual evaluation of the strains present within 
the environment is essential to ensure that the performance characteristics are affected by a 
change in the genotype. Further, it is important to note that our study used the current gold-
standard toxigenic culture as reference standard. Some previous studies within the meta-analysis 
listed in table 2 utilize a reference standard such as the previous gold standard assay, CCNA, or a 
composite gold standard composed of a positive test result on multiple assays. These reference 
standards could have provided results with demonstrated higher performance characteristics. The 
overall conclusion that molecular assays are better assays in comparison to their older 
counterparts is in agreement with other studies.45 
In the second aim of this study, the resulting mean C. difficile score in this study was 
compared between various groups with different combinations of positive results on assays. 
Relationships between individual clinical factors and combinations of results on assays were 
examined as well.  It was found that there was no significant difference between the mean 
clinical score and the combinations of outcomes.  Of particular interest were differences between 
groups 2, 4, and 6, which had at least one positive result on at least one other assay than the cell 
cytotoxicity neutralization assay currently in use. When examining those three groups no 
significant difference was observed. Furthermore, when stratifying toxigenic culture results in 
50 
 
the negative control group no significant difference was found. This could be due to inaccurate 
results from toxigenic culture, or other antibiotic-associated diarrhea. Therefore, refinement 
using our scoring system is unlikely. This contrasts to other literature which has reported 
refinements in performance characteristics through incorporation of patient data.46 
Because of the lack of significant differences among the group and the high proportions 
of patients possessing the three required factors to meet the threshold as having CDI, refinement 
of performance characteristics of the assays is not possible and therefore rejects the hypothesis 
that the assays are simply picking up patients colonized with C. difficile.  The majority of 
patients tested had diarrhea, as well as the two main risk factors for CDI which are antimicrobial 
use and inpatient exposure within the previous twelve weeks. Notably, there was one 
discrepancy with one patient who lacked diarrhea in retrospective chart review (Table 10), who 
should have had an unformed stool for processing.  It is possible to also make the conclusion that 
clinicians are properly utilizing C. difficile toxin testing when indicated and submitting only 
when risk factors and symptoms are present. A potential bias exists within this study however, 
exists, in that a requirement in this study was the processing of unformed stools which could 
have led to a higher number of CDI patients.   
The third aim of this study sought to examine a potential relationship between semi-
quantitative culture results and clinical C. difficile likelihood score, and individual patient 
factors. No significant differences were observed between the likelihood score among all the 
semi-quantitative culture.  It was also found that a significant proportion of patients possessed 
the three clinical factors for C. difficile. Further, there were no observable trends between 
increasing colony forming units indicated by a higher category and being positive on any one 
assay. Therefore, the concentration of the organism isolated would not be a good predictor of 
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disease likelihood with the scoring system used in this study. Therefore, one would not be able to 
differentiate between asymptomatic and diseased individuals by semi-quantitative results. 
Previously reported data have indicated that asymptomatic carriers have a lower mean colony 
forming units per gram as compared to symptomatic patients.47 This result contrasts to our study 
which suggests that all concentrations of C. difficile forming units would likely correspond to 
patients with true CDI. 
Noteworthy, independent of the clinical data, is the fact that there was a greater 
percentage of positive assays for newer molecular assays at all semi-quantitative levels compared 
to both EIA or CCNA assays with at least 50% positive results.  This could be due to the ability 
of the newer molecular methods to potentially better detect C. difficile as it amplifies the toxin B 
gene.  Nevertheless, in this study we rejected the hypothesis that excess asymptomatic carriers 
were detected. 
Based on only attributes of performance characteristics alone, at this point it is advisable 
that real-time polymerase chain reaction assay be used for routine clinical care as it amplifies the 
tcdB gene, which has the is less likely to possess mutations which do not allow for detection. 
Furthermore, considering that this assay is relatively new with a FDA approval in July 2010. 
Further studies on the ability of iLAMP assays to detect known toxigenic tcdA-/tcdB+ strains 
need to be performed to predict the performance characteristics if an outbreak were to occur 
within the healthcare institution. If future data suggests that iLAMP assays targeting tcdA are 
highly effective, a new recommendation could be made in conjunction with cost and timeliness. 
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5.1 FUTURE DIRECTIONS 
While the data obtained from this study on performance characteristics independent of clinical 
data could assist in the selection of a new assay for routine use, and render any need for future 
work unnecessary, other evaluations could be performed in an attempt to refine and build upon 
this study.  The C. difficile likelihood score used in this experiment was a novel scoring system 
which had not been previously used, therefore, its use as a predictor of C. difficile had not been 
validated in a large cohort of patients. Any resulting adjustments in the scoring system from a 
validation study would warrant further study as it relates to performance characteristics. 
Additionally, the development of other scoring systems should be explored. Continual evaluation 
will need to be performed on all assays to ensure that these assays possess the highest levels of 
accuracy over time. This is especially true when examining performance characteristics of 
molecular assays, as the distribution of toxinotypes within the medical institution could change 
favoring A-/B+ toxinotypes. This would be problematic if the target of the molecular assay is the 
tcdA gene. Because of this fact, further studies need to be performed to test the ability of iLAMP 
assays to detect known A-/B+ strains. 
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APPENDIX A: GLOSSARY OF TERMS 
ANAEROBIC: Term used to describe conditions with an absence of oxygen. 
ANAMNESTIC: A term relating to rapid enhanced immune response upon encounter with 
previously encountered antigen. 
ANTIBODY:  A protein molecule which binds to an antigen and neutralizes them or prepare for 
further elimination by phagocytes. Antibodies are produced by B-lymphocytes. 
ANTIMICROBIAL: Substances with active ingredients which kill pathogens including bacteria 
and fungi. 
ASSAY: A procedure in molecular biology and laboratory medicine to quantitatively assess the 
presence of a substance or organism. 
BACILLUS: A rod-shaped bacterium. 
BANDEMIA:  An excess of band cells or immature lymphocytes in the blood released by bone 
marrow usually during periods of infection or inflammation. Bandemia is an indicator of possible 
CDI. 
COLECTOMY: A surgical procedure involving resection of the colon. 
COMORBIDITIES: A medical term used to describe secondary diseases in addition to the 
primary disease. 
CYCLE THRESHOLD VALUE (CT):  Defined as the PCR cycle where enough amplification 
of the nucleic acid amplification has occurred to generate a fluorescent signal which can be 
detected. 
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CYTOTOXIN: A substance which has toxic effects on cells. 
DISINFECTANTS: Substances used to kill or inhibit growth of microorganisms on inanimate 
objects (e.g. Fomites). 
ENDEMIC: A term used in epidemiology to describe a continual presence of disease within the 
population. 
ENTEROTOXIN: A protein toxin released by a microorganism which primarily affects the 
intestine. 
EPIDEMIC: A term used in epidemiology to describe presence of disease in with incidence 
levels greater than expected. 
ELECTRON MICROSCOPY: An advanced form of microscopy which utilizes a beam of 
electrons to produce a highly magnified image. 
ENDOSCOPY: A procedure where a medical instrument (endoscope) used to image inside the 
body cavity. 
FULMINANT: Disease which with sudden, rapid onset with ability to be lethal. 
ILEOSTOMY: Surgical procedure involving routing the ileum portion of the small intestine to 
the surface of the skin, allowing waste to collect to an external pouch. This procedure allows 
bypass of the large intestine (colon).  
IMMUNITY: A term used to describe ability of an organism to resistance infection or disease.  
IMMUNOSUPPRESSION: A term used to describe a state with decreased resistance to 
infection or disease (immunity). 
INCUBATION: Used in the medical context to describe time between exposure and time 
patient starts exhibiting symptoms. 
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INVASIVE: A medical procedure involving a breach of the skin. 
LEUKOCYTOSIS: A medical term used to describe an increase of leukocytes (white blood 
cells) above the normal range in the blood. 
LOCUS: A term used in the context of genetics to describe the position of a gene on a 
chromosome. 
MEGACOLON: Abnormal dilation of colon, accompanied by paralysis, and tumor like masses 
called fecalomas. 
NEGATIVE PREDICTIVE VALUE: A statistical measure used in epidemiology defined by 
the number of true negatives divided by the number of negative results defined by a diagnostic 
assay. In other words, negative predictive value is defined as the number of true negatives 
divided by the sum of true negatives and false negatives. This measure is typically used to 
measure performance of a binary diagnostic assay. 
NOSOCOMIAL: A term meaning hospital origin, usually used in context of hospital acquired 
infections. 
PATHOGENECITY: A term used to describe ability of pathogen to cause infectious disease. 
PATHOGENESIS:  A mechanism by which a disease in the host is caused by a pathogen.  
POSITIVE PREDICTIVE VALUE: a statistical measure used in epidemiology defined by the 
number of true positives divided by the number of positive results defined by a diagnostic assay. 
In other words, positive predictive value is defined as the number of true positives divided by the 
sum of true positives and false positives. This measure is typically used to measure performance 
of a binary diagnostic assay. 
PROBIOTICS: Live microorganism which provide positive benefits to the host organism.  
RESERVOIR: Conditions where the infectious agent lives, grows and multiplies. 
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RETROSPECTIVE: A term used in medicine and epidemiology to describe the review of 
previously occurring medical history. 
SANITATION: Means of improving and promoting health through improved hygiene and 
prevention measures.  
SENSITIVITY: A measure to measure the performance characteristics of a binary diagnostic 
assay. Sensitivity rate is defined the number of true positives divided by the sum of number of 
true positives and number of false negatives.  Stated differently, it is the probability of a positive 
assay given the presence of the condition being examined.  
SPECIFICITY: A measure is to measure the performance characteristics of a binary diagnostic 
assay. Specificity is defined as the number of true negatives divided by the sum of the number of 
true negatives and false positives. State differently, it is the probability of a negative assay given 
the presence of the condition being examined. 
SPORULATION: Term used to describe the active production of spores. 
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APPENDIX B: ACRONYMS 
CCNA: Cell cytotoxicity neutralization assay 
CDI : Clostridium difficile associated diarrhea 
CDC: Centers for Disease Control 
CdtA: Clostridium difficile transferase subunit A 
CdtB: Clostridium difficile transferase subunit B 
CPE: Cytopathic effects 
CT: Computerized tomography 
Ct Value: Cycle threshold value  
EIA: Enzyme immunoassay 
FMT: Fecal microbiota transplant 
GDH: Glutamate dehydrogenase 
HAI: Hospital acquired infections 
IDSA: Infectious Diseases Society of America 
iLAMP: Isothermal loop mediated amplification 
IVIG: Intravenous immunoglobulin 
MRSA: Methicillin resistant Staphylococcus aureus 
PPI: Proton pump inhibitors 
PCR: Polymerase chain reaction 
RT-PCR: Real-time polymerase chain reaction 
SHEA: Society for Healthcare Epidemiology of America 
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tcdA: Clostridium difficile toxin A 
tcdB: Clostridium difficile toxin B 
tcdC: Clostridium difficile toxin C 
tcdE: Clostridium difficile toxin E 
tcdR: Clostridium difficile toxin R 
UPMC: University of Pittsburgh Medical Center 
VRE: Vancomycin resistant Enterococcus 
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